| Administration route |
None |
| Dosage |
3E6 cells/kg, 6E6 cells/kg, 1E7 cells/kg |
| Donor type |
Allogeneic |
| Pts |
9 |
| Age |
Child, Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
9/9(CR at 28 dyas). The overall response rates (ORR) were 100% (9/9), 88.9% (8/9), and 75% (6/8) at 3 month, 6 month, and 12 month, respectively. The 1-year progression-free and overall survival were 77.8% and 85.7%, respectively. |
| Adverse reactions |
Three patients had acute graft-versus-host-disease (grade I, n = 1; grade II, n = 1; grade IV, n = 1) and all resolved after treatment. |
| References |
PMID:
38204488
|
|